Galecto Inc., whose recent SEC reports identify the registrant as Damora Therapeutics, Inc. following Galecto's acquisition of privately held Damora Therapeutics in November 2025, files disclosures covering biotechnology corporate structure, governance, and equity compensation. Form 8-K reports document executive officer appointments and departures, related compensation arrangements, and changes in the registrant's independent registered public accounting firm.
Proxy materials describe board matters, executive compensation, equity-award information, pay-versus-performance data, shareholder voting items, and governance procedures. The filing record also reflects public-company reporting around Galecto/Damora corporate status and clinical-stage therapeutic development.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics, Inc. reported that director Christopher W. Cain was granted a stock option covering 37,313 shares of common stock at an exercise price of $23.05 per share. The option expires on March 23, 2036 and vests in equal monthly installments through March 23, 2029, conditioned on his continued service.
According to the disclosure, Cain holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, is required to turn over any net cash or stock from the option to Fairmount, and therefore disclaims beneficial ownership of both the option and the underlying shares. Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Damora Therapeutics, Inc. reported that director Christopher W. Cain was granted a stock option covering 37,313 shares of common stock at an exercise price of $23.05 per share. The option expires on March 23, 2036 and vests in equal monthly installments through March 23, 2029, conditioned on his continued service.
According to the disclosure, Cain holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, is required to turn over any net cash or stock from the option to Fairmount, and therefore disclaims beneficial ownership of both the option and the underlying shares. Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.
Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.
Damora Therapeutics, Inc. director Michael Landsittel filed an initial ownership report on Form 3. This filing establishes his status as a reporting insider and provides a baseline record of his holdings in Damora Therapeutics, although no specific transactions or share amounts are detailed in the available data.
Damora Therapeutics, Inc. director Michael Landsittel filed an initial ownership report on Form 3. This filing establishes his status as a reporting insider and provides a baseline record of his holdings in Damora Therapeutics, although no specific transactions or share amounts are detailed in the available data.
Damora Therapeutics announced a major leadership and board refresh. The Board appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and she will also join the Board. Her offer includes a $695,000 base salary, a target bonus equal to 55% of salary, 500,000 restricted stock units vesting over four years, and options to purchase 1,500,000 shares vesting over four years, with enhanced severance and accelerated vesting protections around a change in control.
Current COO Sherwin Sattarzadeh will step down as principal executive officer but remain Chief Operating Officer. Directors Amit Munshi, Carl Goldfischer and Jayson Dallas resigned, with their equity awards fully accelerated, and the Board size was reduced from seven to six. Michael Landsittel and Cameron Turtle were appointed as Class III directors and will receive options under the 2026 Equity Incentive Plan, while Peter Harwin was named Board chair. Damora also updated compensation and severance terms for General Counsel Garrett Winslow, including a $440,000 salary, a 40% target bonus and options for 250,000 shares.
Damora Therapeutics announced a major leadership and board refresh. The Board appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and she will also join the Board. Her offer includes a $695,000 base salary, a target bonus equal to 55% of salary, 500,000 restricted stock units vesting over four years, and options to purchase 1,500,000 shares vesting over four years, with enhanced severance and accelerated vesting protections around a change in control.
Current COO Sherwin Sattarzadeh will step down as principal executive officer but remain Chief Operating Officer. Directors Amit Munshi, Carl Goldfischer and Jayson Dallas resigned, with their equity awards fully accelerated, and the Board size was reduced from seven to six. Michael Landsittel and Cameron Turtle were appointed as Class III directors and will receive options under the 2026 Equity Incentive Plan, while Peter Harwin was named Board chair. Damora also updated compensation and severance terms for General Counsel Garrett Winslow, including a $440,000 salary, a 40% target bonus and options for 250,000 shares.
Damora Therapeutics is repositioning as a hematology-focused biopharmaceutical company built around antibodies targeting mutant calreticulin (mutCALR) in myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, is a monoclonal antibody engineered for higher potency against Type 1 and Type 2 mutCALR and longer half-life than a reference mutCALR antibody with the same mechanism as INCA033989, aiming to enable convenient subcutaneous dosing.
The company plans to file IND or CTA submissions for DMR-001 in mid-2026 and start a Phase 1 trial in ET and MF, with proof‑of‑concept readouts expected beginning mid‑2027. Follow-on candidates DMR-002 and DMR-003 are designed to broaden coverage across the mutCALR disease spectrum, with planned regulatory filings in the second half of 2026 and in 2027, respectively.
Damora acquired private “Pre‑Acquisition Damora” via a stock‑for‑stock asset acquisition and assumed an extensive option and research collaboration with Paragon Therapeutics, including options on DMR‑001, DMR‑002 and DMR‑003. To fund this strategy, it completed a $285 million PIPE in November 2025 and a follow‑on underwritten offering raising approximately $297.3 million in net proceeds in February 2026, alongside a new $150.0 million at‑the‑market program.
Damora Therapeutics is repositioning as a hematology-focused biopharmaceutical company built around antibodies targeting mutant calreticulin (mutCALR) in myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, is a monoclonal antibody engineered for higher potency against Type 1 and Type 2 mutCALR and longer half-life than a reference mutCALR antibody with the same mechanism as INCA033989, aiming to enable convenient subcutaneous dosing.
The company plans to file IND or CTA submissions for DMR-001 in mid-2026 and start a Phase 1 trial in ET and MF, with proof‑of‑concept readouts expected beginning mid‑2027. Follow-on candidates DMR-002 and DMR-003 are designed to broaden coverage across the mutCALR disease spectrum, with planned regulatory filings in the second half of 2026 and in 2027, respectively.
Damora acquired private “Pre‑Acquisition Damora” via a stock‑for‑stock asset acquisition and assumed an extensive option and research collaboration with Paragon Therapeutics, including options on DMR‑001, DMR‑002 and DMR‑003. To fund this strategy, it completed a $285 million PIPE in November 2025 and a follow‑on underwritten offering raising approximately $297.3 million in net proceeds in February 2026, alongside a new $150.0 million at‑the‑market program.
Damora Therapeutics, Inc., formerly Galecto, Inc., has changed its corporate name and will begin trading on Nasdaq under the new symbol “DMRA” starting March 10, 2026. The name change does not affect shareholder voting rights or the validity of existing common stock.
The company reported preliminary, unaudited cash and cash equivalents of approximately $535 million as of February 28, 2026, supporting plans to advance its mutant calreticulin–targeted pipeline. Damora expects to submit regulatory applications for lead antibody DMR-001 in mid‑2026 and aims for two clinical proof‑of‑concept datasets beginning mid‑2027, with cash runway anticipated into Phase 3 development of DMR-001.
Galecto, Inc. reports beneficial ownership by Ikarian-related investors of 335,710 shares of Common Stock. The filing states the shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts, representing 0.6% of the class based on 60,232,620 shares outstanding as of February 12, 2026.
The statement is a joint filing by Ikarian Capital, LLC and Neil Shahrestani that discloses shared voting and dispositive power over the 335,710 shares.
Venrock-affiliated investment entities reported a significant passive stake in Galecto, Inc. They disclosed beneficial ownership of 3,603,595 shares of Galecto common stock, representing 6.0% of the company’s outstanding shares.
The holdings are spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P., with management entities VHCP Management III, LLC and VHCP Management EG, LLC, and individuals Nimish Shah and Bong Y. Koh also listed as reporting persons. The 6.0% figure is based on 60,232,620 Galecto shares outstanding as of February 12, 2026. The group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Galecto.
Jain Global LLC, Jain Holdings LLC, and Robert Jain reported beneficial ownership of 120,566 shares of Galecto, Inc. common stock, representing 7.5% of the company. This stake is held through Jain Global Master Fund Ltd, for which Jain Global serves as investment manager.
The percentage is based on 1,597,321 shares outstanding as of December 29, 2025, as reported in Galecto’s definitive proxy statement. The securities are certified as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Galecto.